Dr. Dana M. Bonezzi, MD
Internal Medicine (Internal Medicine Physician)
3727 Friendsville Rd, Suite 2
Wooster, OH 44691
Who else practices at this address →
Wayne County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Nebraska College of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 137
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Nebraska College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
OH license 35073190B
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Aultman Hospital Canton, OH
- Wooster Community Hospital Wooster, OH
Medical groups
- Comprehensive Internal Medicine Inc (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 137
- Services billed
- 858
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 236 | 101 |
| Established patient office or other outpatient visit, 20-29 minutes | 95 | 61 |
| Established patient office or other outpatient visit, 10-19 minutes | 57 | 46 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 44 | 12 |
| Hemoglobin a1c level | 37 | 25 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 32 | 32 |
| Administration of influenza virus vaccine | 30 | 30 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 19 | 19 |
| Aspiration and/or injection of fluid from medium joint | 19 | 11 |
| Urinalysis, manual test | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 50 payments worth $885 in total to this clinician.
| AbbVie Inc. | $249 |
|---|---|
| Pfizer Inc. | $146 |
| Phathom Pharmaceuticals, Inc. | $77.81 |
| Radius Health, Inc. | $55.18 |
| Astellas Pharma US Inc | $50.15 |
| Xeris Pharmaceuticals, Inc. | $36.81 |
| Abbott Laboratories | $33.22 |
| Novo Nordisk Inc | $30.79 |
| Food and Beverage | $885 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $106,143 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047444 - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047457 - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulm…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.